Since mutant TP53 is the most common driver or co-driver in various cancer types, novel therapies that reactivate mutant p53 protein and/or prevent degradation of wild-type p53 have the potential to be promising agents for use alone or in combination therapies addressing the problem of drug resistance (44–46). Here, TP53 is linked to cancer.